Agrylin

Agrylin

anagrelide

Manufacturer:

Takeda

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Anagrelide HCl
Indications/Uses
Reduction of elevated platelet counts in patients w/ essential thrombocythaemia (ET) intolerant to current therapy or whose elevated platelet counts are not reduced to an acceptable level by current therapy.
Dosage/Direction for Use
Initially 1 mg daily in 2 divided doses for at least 1 wk, may be titrated using not >0.5 mg daily increments. Max single dose: Not to exceed 2.5 mg daily.
Administration
May be taken with or without food: Swallow whole, do not crush/dissolve.
Contraindications
Hypersensitivity. Moderate or severe hepatic or renal impairment.
Special Precautions
Patients w/ known risk factors for QT prolongation interval eg, congenital long QT syndrome, known history of acquired QTc prolongation, medicinal products known to prolong QTc interval & hypokalaemia; hypomagnesaemia; known or suspected heart disease; pulmonary HTN. Not recommended in patients w/ elevated transaminases (>5 times upper limit of normal). Monitor complete blood count (eg, Hb, WBC & platelet count); assess liver & renal function & electrolytes. Regularly monitor ECG or echocardiography prior to & during treatment. Not recommended in concomitant use w/ other PDE III inhibitors eg, milrinone, amrinone, enoximone, olprinone, cilostazol. Concomitant use w/ acetylsalicylic acid. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May affect ability to drive & use machines. Renal or hepatic impairment. Not recommended in moderate or severe hepatic impairment. Women of childbearing potential should use effective contraception during treatment. Not recommended during pregnancy. Not to be used during lactation. Childn & adolescents. Elderly >60 yr.
Adverse Reactions
Headache. Anaemia; fluid retention; dizziness; tachycardia, palpitations; diarrhoea, vomiting, abdominal pain, nausea, flatulence; rash; fatigue.
Drug Interactions
Influenced clearance w/ CYP1A2 inhibitors eg, fluvoxamine, enoxacin. Decreased exposure w/ CYP1A2 inducers eg, omeprazole. Potential interaction w/ theophylline. Exacerbated effects of PDE III inhibitors eg, milrinone, enoximone, amrinone, olprinone, cilostazol. Potentiated effects of other drugs known to inhibit or modify platelet function eg, acetylsalicylic acid. Intestinal disturbances & compromised absorption of homonal OCs.
ATC Classification
L01XX35 - anagrelide ; Belongs to the class of other antineoplastic agents. Used in the treatment of cancer.
Presentation/Packing
Form
Agrylin cap 0.5 mg
Packing/Price
100's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in